Australia markets closed

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.96+0.18 (+1.67%)
At close: 04:00PM EDT
11.45 +0.49 (+4.47%)
Pre-market: 07:57AM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial

    ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience of a Single Dose of ALLO-501AProtocol Supported by Clinical and Translational Data from Phase 1 Trial Indicating Deep Responses are Achievable with a Single Dose of ALLO-501A When Used with a Lymphodepletion Regimen That Includes an Optimized Dose of ALLO-647 SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: A

  • GlobeNewswire

    Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit

    SOUTH SAN FRANCISCO, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 6:30AM Pacific Time/9:30AM Eastern Time. The webcast will be posted to the Company's website at under the Investors tab in

  • Zacks

    Allogene Therapeutics (ALLO) Down 10.9% Since Last Earnings Report: Can It Rebound?

    Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.